[go: up one dir, main page]

IT1252867B - Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita' - Google Patents

Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'

Info

Publication number
IT1252867B
IT1252867B ITMI913510A ITMI913510A IT1252867B IT 1252867 B IT1252867 B IT 1252867B IT MI913510 A ITMI913510 A IT MI913510A IT MI913510 A ITMI913510 A IT MI913510A IT 1252867 B IT1252867 B IT 1252867B
Authority
IT
Italy
Prior art keywords
progesterone
compositions containing
pharmaceutical compositions
bioavailability
containing high
Prior art date
Application number
ITMI913510A
Other languages
English (en)
Inventor
Sergio Rosini
Fabio Carli
Original Assignee
Gentili Ist Spa
Vectorpharma Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentili Ist Spa, Vectorpharma Int filed Critical Gentili Ist Spa
Priority to ITMI913510A priority Critical patent/IT1252867B/it
Publication of ITMI913510A0 publication Critical patent/ITMI913510A0/it
Priority to AU32578/93A priority patent/AU3257893A/en
Priority to PCT/EP1992/002982 priority patent/WO1993012797A1/en
Publication of ITMI913510A1 publication Critical patent/ITMI913510A1/it
Application granted granted Critical
Publication of IT1252867B publication Critical patent/IT1252867B/it

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilità costituite da progesterone supportato su un materiale scelto nel gruppo costituito da ?-ciclodestrina e da polivinilpirrolidone reticolato, unitamente a sostanze eccipienti di usuale impiego nella tecnica farmaceutica, utili nella terapia delle forme di insufficienza di progesterone.
ITMI913510A 1991-12-31 1991-12-31 Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita' IT1252867B (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITMI913510A IT1252867B (it) 1991-12-31 1991-12-31 Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
AU32578/93A AU3257893A (en) 1991-12-31 1992-12-23 Pharmaceutical compositions containing natural progesterone having a high biological availability
PCT/EP1992/002982 WO1993012797A1 (en) 1991-12-31 1992-12-23 Pharmaceutical compositions containing natural progesterone having a high biological availability

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI913510A IT1252867B (it) 1991-12-31 1991-12-31 Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'

Publications (3)

Publication Number Publication Date
ITMI913510A0 ITMI913510A0 (it) 1991-12-31
ITMI913510A1 ITMI913510A1 (it) 1993-07-01
IT1252867B true IT1252867B (it) 1995-06-28

Family

ID=11361454

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI913510A IT1252867B (it) 1991-12-31 1991-12-31 Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'

Country Status (3)

Country Link
AU (1) AU3257893A (it)
IT (1) IT1252867B (it)
WO (1) WO1993012797A1 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19652196A1 (de) * 1996-12-16 1998-06-18 Jenapharm Gmbh Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen
IT1296464B1 (it) * 1997-11-19 1999-06-25 Vectorpharma Int Composizioni farmaceutiche in forma di polveri di polimeri reticolati caricati con farmaci e relativo processo di preparazione mediante
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CN107847506A (zh) 2015-06-22 2018-03-27 来普卡公司 含17‑羟基孕酮酯的口服组合物和相关方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230566B (it) * 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione

Also Published As

Publication number Publication date
ITMI913510A1 (it) 1993-07-01
ITMI913510A0 (it) 1991-12-31
WO1993012797A1 (en) 1993-07-08
AU3257893A (en) 1993-07-28

Similar Documents

Publication Publication Date Title
DK0730444T3 (da) Præparater med opretholdt frigivelse til 24-timers frigivelse af metoprolol.
DK1036058T3 (da) Adamantanderivater
DE69808130D1 (de) Adamantan-derivate
HK1049521A1 (zh) 石版印刷工藝中的高精度方位調整及縫隙控制階段
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
NO903001L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater med forlenget frigivelse.
GB9806632D0 (en) Peptide factor
NO991405L (no) Belagt partikkelformulering
KR0156686B1 (en) Pharmaceutical composition comprising aryl-substituted rhodanine derivatives
PH31073A (en) Pharmaceutical composition and process for the preparation thereof.
IT1252867B (it) Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
AU3743295A (en) Colchicine derivatives and the therapeutical use thereof
EP0670166A3 (en) Pharmaceutical compositions for oral administration.
DE69022957D1 (de) Spanner.
GB9123353D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
ES2115055T3 (es) 1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos.
TR199800765T2 (xx) Otoim�n hastal�klar�n tedavisine mahsus bir farmas�tik bile�im
GB9310075D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
ITRM920535A1 (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
NZ237131A (en) 5-substituted 2',3'-dideoxy-3'-fluorouridine derivatives; preparatory processes and pharmaceutical compositions
OA09301A (fr) "Nouvelle forme galénique orale améliorant la biodisponibilité".
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
NZ240927A (en) Dibenz-oxa-thiocinones; preparatory processes, uses, and pharmaceutical compositions
EP0643060A3 (de) Sulfonylbenzyl-substituierte Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln.

Legal Events

Date Code Title Description
0001 Granted